Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

Common Shareholders and Diluted Earnings per Common Share (Amounts in Millions, except per share figures) Six months ended June 30, 2009 (unaudited) ----------- Special, Purchase Merger and Accounting Acquisition- Other As As Adjust- Related Specified Reconciled Reported ments Items Items (1) -------- ----- ----- ----- --- Net sales $9,040 $- $- $- $9,040 Cost of sales 3,019 (256) (7) - 2,756 Selling, general and administrative 3,119 (3) - - 3,116 Research and development 1,667 (5) (2) - 1,660 Other expense/(income), net 194 - - - 194 Special, merger and acquisition-related charges 104 - (104) - - Equity income (770) - - - (770) ----- - - - ----- Income before income taxes 1,707 264 113 - 2,084 Income tax expense/(benefit) 231 (59) (13) - 303 --- ---- ---- - --- Net income $1,476 $205 $100 $- $1,781 ------ ---- ---- -- ------ Preferred stock dividends 75 - - -
'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 3Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 4Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 5Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 6Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 7Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 8Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 9Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 10First-in-class treatment for acute leukemia 2First-in-class treatment for acute leukemia 3Study finds new relationship between gene duplication and alternative splicing in plants 2Study finds new relationship between gene duplication and alternative splicing in plants 3Blue Belt Technologies Inc Closes Series A Financing 5111 1Blue Belt Technologies Inc Closes Series A Financing 5111 2Blue Belt Technologies Inc Closes Series A Financing 5111 3Abbott Cuts Use of Oil and Coal by 35 Percent 5108 1Abbott Cuts Use of Oil and Coal by 35 Percent 5108 2Abbott Cuts Use of Oil and Coal by 35 Percent 5108 3Urologists Radiologists Patients Benefit From New Clinical Prostate Visualization System 5105 1Urologists Radiologists Patients Benefit From New Clinical Prostate Visualization System 5105 2